April 7 (Reuters) - Cutera Inc , which makes lasers for medical and aesthetic use, said U.S. health regulators approved its device to treat fungal nail infections, sending its shares up 6 percent in extended trade.
Cutera’s GenesisPlus laser will now be used by physicians to treat nail fungus that often causes the toenails to become discolored, thickened and separated from the nail bed.
“A significant number of affected patients are dissatisfied with the current treatment options, including topical therapies and oral medications,” said Chief Executive Kevin Connors.
Patients suffering from fungal nail infections now have a fast and effective treatment, without the risks of serious side-effects, he added.
Shares of the company were up 6 percent at $9.15 in after-market trade. They closed at $8.60 on Thursday on Nasdaq. (Reporting by Anand Basu in Bangalore; Editing by Sriraj Kalluvila)